Evogene (NASDAQ:EVGN) Shares Pass Above 50 Day Moving Average – Here’s What Happened

Shares of Evogene Ltd. (NASDAQ:EVGN) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.82 and traded as high as $0.8299. Evogene shares last traded at $0.7801, with a volume of 68,314 shares trading hands.

Evogene Trading Down 1.0%

The stock has a 50 day moving average price of $0.82 and a two-hundred day moving average price of $1.01. The company has a market cap of $6.80 million, a price-to-earnings ratio of -0.67 and a beta of 1.39.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Saturday, February 14th. The biotechnology company reported ($0.61) earnings per share for the quarter. The company had revenue of $0.31 million during the quarter. Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in EVGN. XTX Topco Ltd bought a new stake in shares of Evogene in the 4th quarter valued at $25,000. Jane Street Group LLC increased its position in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares in the last quarter. Finally, Citadel Advisors LLC increased its position in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares in the last quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.